Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of JNJ-95597528 and a Proof of Mechanism Study in Participants with Mild to Moderate Asthma

2024-517644-62-00 Protocol 95597528EDI1001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 30 Jun 2025 · Status Ongoing, recruiting · 2 EU/EEA countries · 3 sites · Protocol 95597528EDI1001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 112
Countries 2
Sites 3

Mild to Moderate Asthma

Key facts

Sponsor
Janssen Cilag International
Participant type
Patients, Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08]
Trial duration
30 Jun 2025 → ongoing
Decision date (initial)
2025-06-03
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Mild to Moderate Asthma

VersionLevelCodeTermSystem organ class
20.0 PT 10003553 Asthma 100000004855

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen Cilag International

Sponsor organisation
Janssen Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Locations

2 EU/EEA countries · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruiting 20 1
Germany Ongoing, recruiting 26 2
Rest of world
Australia
66

Investigational sites

Belgium

1 site · Ongoing, recruiting
SGS Belgium
SGS NV - Clinical Pharmacology Unit, Drie Eikenstraat 655, 2650, Edegem

Germany

2 sites · Ongoing, recruiting
IKF Pneumologie GmbH & Co. KG
lnstitut fuer klinische Forschung Pneumologie, 2nd Floor, Schaumainkai 101-103, Frankfurt Am Main
Charite Research Organisation GmbH
Medical Operations, Chariteplatz 1, Mitte, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2025-09-05 2025-09-05
Germany 2025-06-30 2025-06-30

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-02-06 Belgium Acceptable
2025-06-02
2025-06-03
2 SUBSTANTIAL MODIFICATION SM-1 2025-07-02 Belgium Acceptable 2025-08-26
3 SUBSTANTIAL MODIFICATION SM-2 2025-07-08 Acceptable 2025-08-19
4 SUBSTANTIAL MODIFICATION SM-3 2025-09-19 Belgium Acceptable
2025-11-25
2025-11-27
5 NON SUBSTANTIAL MODIFICATION NSM-1 2026-02-12 Belgium Acceptable
2025-11-25
2026-02-12
6 NON SUBSTANTIAL MODIFICATION NSM-2 2026-04-23 Belgium Acceptable
2025-11-25
2026-04-23